![Karlheinz Schmelig](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karlheinz Schmelig
Directeur/Membre du Conseil chez
BIOFRONTERA AG
Profil
Karlheinz Schmelig currently works at CEVEC Pharmaceuticals GmbH, as Director, Chundsell Medicals AB, as Director, TACALYX GmbH, as Director, Biofrontera AG, as Member-Supervisory Board from 2021, Creathor Venture Management GmbH, as Managing Partner from 2004, Phenex Pharmaceuticals AG, as Member-Supervisory Board, Cryotherapeutics SA, as Member-Supervisory Board, and AYOXXA Biosystems GmbH, as Member-Supervisory Board.
Mr. Schmelig also formerly worked at Prostatype Genomics AB, as Independent Director from 2013 to 2023.
Mr. Schmelig received his undergraduate degree from Duale Hochschule Baden-Württemberg Mannheim and Masters Business Admin degree from Kelley School of Business.
Postes actifs de Karlheinz Schmelig
| Sociétés | Poste | Début |
|---|---|---|
| BIOFRONTERA AG | Directeur/Membre du Conseil | 14/12/2021 |
Creathor Venture Management GmbH
 Creathor Venture Management GmbH Investment ManagersFinance Creathor Venture invests primarily in Germany, France and Switzerland as well as in the rest of Europe. The firm focuses on technology and health care sectors. It provides financing for seed and early stage capital requirements with an investment size of EUR 0.05 - 2.5 million. It acts as lead investor and also acquires minority stakes. | Private Equity Investor | 01/01/2004 |
CEVEC Pharmaceuticals GmbH
 CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical molecules | Directeur/Membre du Conseil | - |
Phenex Pharmaceuticals AG
 Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Specializes in identification and analysis of selective drug candidates for nuclear receptors using its SNuRM technology | Directeur/Membre du Conseil | - |
Chundsell Medicals AB
 Chundsell Medicals AB BiotechnologyHealth Technology Develops and markets novel molecular diagnostics for the treatment of cancer | Directeur/Membre du Conseil | - |
AYOXXA Biosystems GmbH
 AYOXXA Biosystems GmbH BiotechnologyHealth Technology Provides biotechnology research and development services | Directeur/Membre du Conseil | - |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Directeur/Membre du Conseil | - |
Cryotherapeutics SA
 Cryotherapeutics SA Medical SpecialtiesHealth Technology Develops and markets a cryotherapy system for the treatment of coronary artery diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Karlheinz Schmelig
| Sociétés | Poste | Fin |
|---|---|---|
| PROSTATYPE GENOMICS AB | Directeur/Membre du Conseil | 30/06/2023 |
Formation de Karlheinz Schmelig
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
46
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical molecules | Health Technology |
Biofrontera AG
 Biofrontera AG Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops and distributes dermatological products | Health Technology |
Creathor Venture Management GmbH
Creathor Venture Management GmbH Investment ManagersFinance Creathor Venture invests primarily in Germany, France and Switzerland as well as in the rest of Europe. The firm focuses on technology and health care sectors. It provides financing for seed and early stage capital requirements with an investment size of EUR 0.05 - 2.5 million. It acts as lead investor and also acquires minority stakes. | Finance |
Phenex Pharmaceuticals AG
Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Specializes in identification and analysis of selective drug candidates for nuclear receptors using its SNuRM technology | Health Technology |
Cryotherapeutics SA
Cryotherapeutics SA Medical SpecialtiesHealth Technology Develops and markets a cryotherapy system for the treatment of coronary artery diseases | Health Technology |
Duale Hochschule Baden-Württemberg Mannheim
 Duale Hochschule Baden-Württemberg Mannheim Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AYOXXA Biosystems GmbH
AYOXXA Biosystems GmbH BiotechnologyHealth Technology Provides biotechnology research and development services | Health Technology |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chundsell Medicals AB
Chundsell Medicals AB BiotechnologyHealth Technology Develops and markets novel molecular diagnostics for the treatment of cancer | Health Technology |
TACALYX GmbH
TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services Develops therapeutics targeting cancer-specific carbohydrate antigens for metastatic malignant tumors | Commercial Services |
Prostatype Genomics AB
 Prostatype Genomics AB Medical SpecialtiesHealth Technology Develops, manufactures and markets prognostic genetic test prostatype equipment | Health Technology |
